BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2022 12:50:19 PM | Browse: 155 | Download: 297
 |
Received |
|
2022-08-04 05:43 |
|
Peer-Review Started |
|
2022-08-04 05:47 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-10-12 01:49 |
|
Revised |
|
2022-10-20 05:42 |
|
Second Decision |
|
2022-11-08 03:04 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-11-08 08:15 |
|
Articles in Press |
|
2022-11-08 08:15 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-11-04 12:51 |
|
Typeset the Manuscript |
|
2022-11-11 02:21 |
|
Publish the Manuscript Online |
|
2022-12-02 12:50 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Minireviews |
| Article Title |
Circulating angiotensin converting enzyme 2 and COVID-19
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana, Tawithep Leowattana and Pathomthep Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, MD, MSc, PhD, Professor, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi road, Rachatawee, Bangkok 10400, Bangkok, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
Circulating angiotensin converting enzyme 2; Coronavirus disease 2019; Disease severity; Clinical outcome; Severe acute respiratory syndrome coronavirus 2 infection |
| Core Tip |
Recently, conflicting results on circulating ACE2 (cACE2) levels in coronavirus disease 2019 (COVID-19) patients vs healthy people with low cACE2 values were published. cACE2 levels and activity were shown to be increased in severe COVID-19 patients. However, others showed no change or decreased cACE2 in severe COVID-19 patients compared to pre-pandemic controls. Furthermore, it is unclear how SARS-CoV-2 infection and recovery impact the cACE2 level. cACE2 levels increased throughout the first 2 wk of the acute phase of COVID-19. cACE2 levels, on the other hand, were elevated for 1-3 mo after infection and decreased by 4 mo of the illness course. The purpose of this review is to look at the relationship between SARS-CoV-2 and cACE2. A variety of prospective therapeutic options for inhibiting SARS-CoV-2 infection is also explored. |
| Publish Date |
2022-12-02 12:50 |
| Citation |
Leowattana W, Leowattana T, Leowattana P. Circulating angiotensin converting enzyme 2 and COVID-19. World J Clin Cases 2022; 10(34):12470-12483 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i34/12470.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i34.12470 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
